血清肿瘤标志物与肺癌肝转移的相关性

IF 1.8 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES
Xiaoyuan Bu, Xintong Shi, Yingjun Wu, Yinxiang Wu, Lu Li, Liping Gao, Zhiwei Xiao, Jiquan Chen
{"title":"血清肿瘤标志物与肺癌肝转移的相关性","authors":"Xiaoyuan Bu,&nbsp;Xintong Shi,&nbsp;Yingjun Wu,&nbsp;Yinxiang Wu,&nbsp;Lu Li,&nbsp;Liping Gao,&nbsp;Zhiwei Xiao,&nbsp;Jiquan Chen","doi":"10.1155/2024/5195652","DOIUrl":null,"url":null,"abstract":"<div>\n <p><b>Purpose:</b> To investigate the relationship between the changes of lactate dehydrogenase (LDH), neuron-specific enolase (NSE), keratin-19 fragment antigen 21-1 (cyfra21-1), and liver metastases of lung cancer.</p>\n <p><b>Methods:</b> Eighty patients who had lung cancer that had spread to their liver diagnosed in our hospital from October 2021 to October 2023 (Group A), 80 individuals with advanced lung cancer who have metastasized to other sites (Group B), and 80 individuals with lung cancer who have not spread (control group) were selected as the study objects. LDH, NSE, and serum cyfra21-1 levels of patients in the three groups were detected, and pathological results were used as the diagnostic gold standard. ROC curves were drawn to examine the clinical value of NSE, cyfra21-1, and LDH levels in the distinct types of lung cancer identification of liver metastases.</p>\n <p><b>Results:</b> There was no remarkable variation in pathological types among the three groups (<i>p</i> &gt; 0.05), but there were remarkable variations in TNM stage and lymph node metastasis among the three groups (<i>p</i> &lt; 0.05). The levels of cyfra21-1, NSE, and LDH in Group A and Group B were greater compared to those in the control group (<i>p</i> &lt; 0.05), and the levels of cyfra21-1, NSE, and LDH in Group A were greater compared to those in Group B (<i>p</i> &lt; 0.05). The critical value, sensitivity, specificity, and area under the curve (AUC) of serum cyfra21-1 in the distinct identification of liver metastasis of lung cancer were 8.22 ng/mL, 37.42%, 65.18%, and 0.508, respectively. The critical value, sensitivity, specificity, and AUC of NSE for distinct types of lung cancer identification of liver metastases were 23.96 ng/mL, 64.56%, 81.23%, and 0.723, respectively. The critical value, sensitivity, specificity, and AUC of LDH for differential diagnosis of liver metastasis of lung cancer were 304.78 U/L, 75.65%, 85.73%, and 0.821.</p>\n <p><b>Conclusion:</b> The serum levels of NSE, cyfra21-1, and LDH in patients with liver metastasis of lung cancer were remarkably greater compared to patients without liver metastasis, which can be useful as a clinical auxiliary in determining lung cancer metastasis.</p>\n </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5195652","citationCount":"0","resultStr":"{\"title\":\"The Correlation Between Serum Tumor Markers and Liver Metastasis of Lung Cancer\",\"authors\":\"Xiaoyuan Bu,&nbsp;Xintong Shi,&nbsp;Yingjun Wu,&nbsp;Yinxiang Wu,&nbsp;Lu Li,&nbsp;Liping Gao,&nbsp;Zhiwei Xiao,&nbsp;Jiquan Chen\",\"doi\":\"10.1155/2024/5195652\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><b>Purpose:</b> To investigate the relationship between the changes of lactate dehydrogenase (LDH), neuron-specific enolase (NSE), keratin-19 fragment antigen 21-1 (cyfra21-1), and liver metastases of lung cancer.</p>\\n <p><b>Methods:</b> Eighty patients who had lung cancer that had spread to their liver diagnosed in our hospital from October 2021 to October 2023 (Group A), 80 individuals with advanced lung cancer who have metastasized to other sites (Group B), and 80 individuals with lung cancer who have not spread (control group) were selected as the study objects. LDH, NSE, and serum cyfra21-1 levels of patients in the three groups were detected, and pathological results were used as the diagnostic gold standard. ROC curves were drawn to examine the clinical value of NSE, cyfra21-1, and LDH levels in the distinct types of lung cancer identification of liver metastases.</p>\\n <p><b>Results:</b> There was no remarkable variation in pathological types among the three groups (<i>p</i> &gt; 0.05), but there were remarkable variations in TNM stage and lymph node metastasis among the three groups (<i>p</i> &lt; 0.05). The levels of cyfra21-1, NSE, and LDH in Group A and Group B were greater compared to those in the control group (<i>p</i> &lt; 0.05), and the levels of cyfra21-1, NSE, and LDH in Group A were greater compared to those in Group B (<i>p</i> &lt; 0.05). The critical value, sensitivity, specificity, and area under the curve (AUC) of serum cyfra21-1 in the distinct identification of liver metastasis of lung cancer were 8.22 ng/mL, 37.42%, 65.18%, and 0.508, respectively. The critical value, sensitivity, specificity, and AUC of NSE for distinct types of lung cancer identification of liver metastases were 23.96 ng/mL, 64.56%, 81.23%, and 0.723, respectively. The critical value, sensitivity, specificity, and AUC of LDH for differential diagnosis of liver metastasis of lung cancer were 304.78 U/L, 75.65%, 85.73%, and 0.821.</p>\\n <p><b>Conclusion:</b> The serum levels of NSE, cyfra21-1, and LDH in patients with liver metastasis of lung cancer were remarkably greater compared to patients without liver metastasis, which can be useful as a clinical auxiliary in determining lung cancer metastasis.</p>\\n </div>\",\"PeriodicalId\":11953,\"journal\":{\"name\":\"European Journal of Cancer Care\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5195652\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/2024/5195652\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer Care","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/5195652","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

目的:探讨乳酸脱氢酶(LDH)、神经元特异性烯醇化酶(NSE)、角蛋白-19片段抗原21-1(cyfra21-1)的变化与肺癌肝转移之间的关系。 研究方法选取2021年10月至2023年10月在我院确诊的80例肺癌肝转移患者(A组)、80例已转移至其他部位的晚期肺癌患者(B组)和80例未转移的肺癌患者(对照组)作为研究对象。检测三组患者的 LDH、NSE 和血清 cyfra21-1 水平,并以病理结果作为诊断金标准。绘制ROC曲线,研究NSE、cyfra21-1和LDH水平在不同类型肺癌肝转移鉴别中的临床价值。 结果三组患者的病理类型无明显差异(P> 0.05),但三组患者的 TNM 分期和淋巴结转移情况有明显差异(P< 0.05)。A 组和 B 组的 cyfra21-1、NSE 和 LDH 水平均高于对照组(p <;0.05),A 组的 cyfra21-1、NSE 和 LDH 水平高于 B 组(p <;0.05)。血清 cyfra21-1 在肺癌肝转移鉴别中的临界值、敏感性、特异性和曲线下面积(AUC)分别为 8.22 ng/mL、37.42%、65.18% 和 0.508。NSE 对不同类型肺癌肝转移灶鉴别的临界值、灵敏度、特异性和 AUC 分别为 23.96 ng/mL、64.56%、81.23% 和 0.723。LDH 对肺癌肝转移鉴别诊断的临界值、敏感性、特异性和 AUC 分别为 304.78 U/L、75.65%、85.73% 和 0.821。 结论肺癌肝转移患者血清中NSE、cyfra21-1和LDH水平明显高于无肝转移患者,可作为判断肺癌转移的临床辅助指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The Correlation Between Serum Tumor Markers and Liver Metastasis of Lung Cancer

The Correlation Between Serum Tumor Markers and Liver Metastasis of Lung Cancer

Purpose: To investigate the relationship between the changes of lactate dehydrogenase (LDH), neuron-specific enolase (NSE), keratin-19 fragment antigen 21-1 (cyfra21-1), and liver metastases of lung cancer.

Methods: Eighty patients who had lung cancer that had spread to their liver diagnosed in our hospital from October 2021 to October 2023 (Group A), 80 individuals with advanced lung cancer who have metastasized to other sites (Group B), and 80 individuals with lung cancer who have not spread (control group) were selected as the study objects. LDH, NSE, and serum cyfra21-1 levels of patients in the three groups were detected, and pathological results were used as the diagnostic gold standard. ROC curves were drawn to examine the clinical value of NSE, cyfra21-1, and LDH levels in the distinct types of lung cancer identification of liver metastases.

Results: There was no remarkable variation in pathological types among the three groups (p > 0.05), but there were remarkable variations in TNM stage and lymph node metastasis among the three groups (p < 0.05). The levels of cyfra21-1, NSE, and LDH in Group A and Group B were greater compared to those in the control group (p < 0.05), and the levels of cyfra21-1, NSE, and LDH in Group A were greater compared to those in Group B (p < 0.05). The critical value, sensitivity, specificity, and area under the curve (AUC) of serum cyfra21-1 in the distinct identification of liver metastasis of lung cancer were 8.22 ng/mL, 37.42%, 65.18%, and 0.508, respectively. The critical value, sensitivity, specificity, and AUC of NSE for distinct types of lung cancer identification of liver metastases were 23.96 ng/mL, 64.56%, 81.23%, and 0.723, respectively. The critical value, sensitivity, specificity, and AUC of LDH for differential diagnosis of liver metastasis of lung cancer were 304.78 U/L, 75.65%, 85.73%, and 0.821.

Conclusion: The serum levels of NSE, cyfra21-1, and LDH in patients with liver metastasis of lung cancer were remarkably greater compared to patients without liver metastasis, which can be useful as a clinical auxiliary in determining lung cancer metastasis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
European Journal of Cancer Care
European Journal of Cancer Care 医学-康复医学
CiteScore
4.00
自引率
4.80%
发文量
213
审稿时长
3 months
期刊介绍: The European Journal of Cancer Care aims to encourage comprehensive, multiprofessional cancer care across Europe and internationally. It publishes original research reports, literature reviews, guest editorials, letters to the Editor and special features on current issues affecting the care of cancer patients. The Editor welcomes contributions which result from team working or collaboration between different health and social care providers, service users, patient groups and the voluntary sector in the areas of: - Primary, secondary and tertiary care for cancer patients - Multidisciplinary and service-user involvement in cancer care - Rehabilitation, supportive, palliative and end of life care for cancer patients - Policy, service development and healthcare evaluation in cancer care - Psychosocial interventions for patients and family members - International perspectives on cancer care
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信